Claims of efficacy
Switzerland ／ Swissmedic
All statements in professional advertising must be consistent with the medicinal product information last approved by Swissmedic and only indications and uses approved by Swissmedic may be advertised; the statements must be accurate, balanced, factually correct, substantiable and not misleading, and must be based on and reflect the current state of scientific knowledge, with the same consistency requirement applying to advertising to the public.
専門家向け広告のすべての記載はスイスメディックが最後に承認した医薬品情報と一致していなければならず、承認された効能・使用法のみを広告でき、記載は正確・均衡・客観的に正しく立証可能で誤解を招いてはならず、最新の科学的知見に基づいてこれを反映しなければならない（一般向け広告にも同じ一致の要請がかかる）。
Note
Read in German on Fedlex. The Fedlex ELI landing page (https://www.fedlex.admin.ch/eli/cc/2001/519/de) is a JavaScript application that returns no text to a plain fetch, so the consolidated HTML was taken from the Fedlex filestore URL cited here. Art. 5 Abs. 5 further requires that advertising claims refer only to clinical trials conducted under GCP and published or accepted for publication, and to data collections such as meta-analyses or practice reports published in a scientifically recognised medium, quoted verbatim, in full and with a precise source. Art. 5 Abs. 6 and Art. 16 Abs. 4 allow a product, indication, dosage, dosage form or pack to be promoted as 'new' for eighteen months after first authorisation in Switzerland. I swept every monthly consolidation date from January 2020 to December 2026 on the Fedlex filestore and found no version later than 1 January 2020.
Read in German on Fedlex. The Fedlex ELI landing page (https://www.fedlex.admin.ch/eli/cc/2001/519/de) is a JavaScript application that returns no text to a plain fetch, so the consolidated HTML was taken from the Fedlex filestore URL cited here. Art. 5 Abs. 5 further requires that advertising claims refer only to clinical trials conducted under GCP and published or accepted for publication, and to data collections such as meta-analyses or practice reports published in a scientifically recognised medium, quoted verbatim, in full and with a precise source. Art. 5 Abs. 6 and Art. 16 Abs. 4 allow a product, indication, dosage, dosage form or pack to be promoted as 'new' for eighteen months after first authorisation in Switzerland. I swept every monthly consolidation date from January 2020 to December 2026 on the Fedlex filestore and found no version later than 1 January 2020.